GlassScriptPhysician profile
Marc A Clachko
NPI 1417919622
$310.94
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2021: $180.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $44.58 | 2021 | |
| Agile Therapeutics, INC. | $42.50 | 2021 | |
| Evofem Biosciences, INC. | $28.96 | 2021 | |
| Lupin INC. | $28.51 | 2019 | |
| Pfizer INC. | $25.05 | 2019-2021 | |
| Exeltis, USA INC. | $24.92 | 2021 | |
| Avion Pharmaceuticals | $24.00 | 2019-2021 | |
| Celularity INC. | $14.00 | 2019 | |
| Daiichi Sankyo INC. | $13.69 | 2021 | |
| Therapeuticsmd, INC. | $13.61 | 2019 | |
| Abbvie INC. | $13.26 | 2019 | |
| Coopersurgical, INC. | $13.03 | 2019 | |
| Merck Sharp & Dohme LLC | $12.83 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Clachko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.